Imcivree (setmelanotide) is used specifically for the treatment of obesity caused by rare genetic disorders that disrupt the melanocortin-4 receptor (MC4R) pathway. These genetic conditions impair the brain’s ability to regulate hunger and energy expenditure, leading to severe early-onset obesity that is unresponsive to traditional weight-loss methods. Imcivree works by restoring this disrupted pathway, making it an essential therapeutic option for patients with confirmed genetic diagnoses.

• Treats rare genetic obesity
  Imcivree is FDA-approved to treat obesity caused by three rare genetic disorders: POMC deficiency, PCSK1 deficiency, and LEPR deficiency. These conditions result in excessive hunger and severe weight gain from a young age.

• Regulates appetite via MC4R activation
  It is a selective MC4R agonist, designed to restore appetite regulation in individuals whose genetic mutation affects this pathway. It addresses the core dysfunction rather than the symptoms.

• Prevents metabolic dysregulation
  Without treatment, patients may experience complications like insulin resistance, type 2 diabetes, fatty liver, and cardiovascular issues. Imcivree can help prevent or reverse metabolic issues by reducing weight and appetite.

• Improves quality of life
  By reducing persistent hunger (hyperphagia) and supporting weight loss, Imcivree helps patients gain control over eating behaviors and improve daily functioning and social participation.

• Indicated for adults and children (≥6 years)
  Both pediatric and adult patients with a confirmed genetic diagnosis are eligible, making it a versatile treatment option for lifelong care.

• Reduces burden of ineffective interventions
  Traditional weight-loss programs like calorie restriction and exercise are largely ineffective for genetic obesity. Imcivree eliminates years of unsuccessful interventions.

Imcivree works by activating the melanocortin-4 receptor (MC4R), a key receptor in the hypothalamus that plays a central role in regulating hunger and energy expenditure. In individuals with rare gene mutations, this signaling pathway is disrupted, causing persistent hunger and obesity. Imcivree helps restore this function by mimicking the natural signals that the body fails to produce on its own.

• Targets the MC4R pathway directly
  Imcivree binds to and stimulates the MC4R receptor, which is crucial for sending signals of satiety and energy balance to the brain. This helps the body understand when to stop eating.

• Reduces hyperphagia (uncontrollable hunger)
  One of the hallmark symptoms of POMC, PCSK1, and LEPR deficiency is extreme hunger. Imcivree significantly reduces hyperphagia, enabling patients to eat more normally.

• Promotes energy expenditure
  By restoring MC4R signaling, the body is better able to burn calories efficiently, supporting sustainable weight loss without needing drastic lifestyle changes.

• Compensates for defective genetic signaling
  For patients whose bodies do not produce or respond to melanocortin peptides, Imcivree acts as a surrogate, filling in the missing biological function.

• Maintains homeostasis
  In addition to controlling hunger, MC4R is involved in managing overall energy homeostasis, which includes thermogenesis and metabolism regulation.

• Acts selectively
  Imcivree is designed to target only MC4R, reducing off-target effects and enhancing its safety profile compared to non-specific appetite suppressants.

Imcivree is not a general weight-loss medication and is only intended for individuals who have a genetically confirmed diagnosis of one of three specific rare disorders. Qualification is based on the presence of mutations that impair the MC4R pathway, leading to early-onset and persistent obesity.

• POMC deficiency obesity
  Patients with pro-opiomelanocortin (POMC) gene mutations lack key precursors for melanocortin signaling. Imcivree can replace this missing function and reduce extreme hunger.

• PCSK1 deficiency obesity
  PCSK1 mutations lead to impaired peptide processing, affecting multiple hormonal pathways including appetite regulation. These patients typically experience severe obesity and hormonal imbalance.

• LEPR deficiency obesity
  Individuals with leptin receptor (LEPR) mutations cannot respond to leptin, the hormone that signals satiety. Imcivree restores appetite control by bypassing the defective receptor.

• Confirmed genetic testing required
  Patients must undergo genetic testing to confirm mutations in the relevant pathways. Without genetic evidence, Imcivree is not approved for use.

• Age 6 and older
  The medication is approved for both children (6 years and above) and adults who meet the genetic criteria, making it a critical treatment across age groups.

• Not suitable for lifestyle-related obesity
  Imcivree is not intended for weight loss in individuals without a genetic mutation, and has no benefit for common forms of obesity.

No, we do not require a prescription to purchase Imcivree through Reall Pharma. While prescriptions are typically required at traditional pharmacies, we offer a private, direct-to-patient service that removes this barrier, especially for those already diagnosed or continuing prior treatment.

• No doctor’s appointment needed
  You don’t need to see a physician to access your medication—ideal for patients with a confirmed diagnosis and prior treatment experience.

• Faster access for ongoing treatment
  For patients already using Imcivree, we enable seamless refills without delays, helping avoid treatment interruptions.

• Ideal for international customers
  In many countries, genetic obesity medications are unavailable or heavily regulated. We help bridge that gap with worldwide, prescription-free access.

• Discreet, judgment-free ordering
  Our system avoids the often stigmatizing or dismissive treatment some patients experience in traditional settings.

• Eligibility is assumed based on informed request
  We trust that customers who seek Imcivree are acting on prior clinical advice or diagnosis, and our responsibility is to fulfill their need securely and discreetly.

Imcivree is administered as a subcutaneous injection—meaning it is injected just under the skin using a small needle. This route allows the drug to be absorbed efficiently while avoiding the digestive system, which would degrade the medication. Most patients can self-administer the injection once they receive proper instruction.

• Once-daily injection
  Imcivree is typically taken once daily at the same time each day to maintain stable drug levels in the body.

• Subcutaneous route preferred
  The medication is injected under the skin—usually in the abdomen, thigh, or upper arm—rotating sites to prevent irritation or tissue damage.

• Self-administration is possible
  After a brief training session or guidance from a healthcare provider, most patients or caregivers can perform the injection at home confidently.

• Injection technique matters
  It’s important to use a sterile needle, clean the injection site with alcohol, and use the correct angle and depth to ensure full absorption.

• Use immediately after withdrawal
  The injection should be administered right after drawing from the vial to maintain potency and sterility.

• Cold chain must be maintained
  The drug should be kept refrigerated and not left at room temperature for long durations before administration.

While Imcivree is generally well tolerated, it may cause side effects in some individuals. Most adverse effects are mild to moderate in severity and often resolve over time. However, it’s important to be aware of all possible reactions so that patients can monitor their health during treatment and seek medical attention if necessary.

• Skin pigmentation (hyperpigmentation)
  One of the most commonly reported side effects is increased skin darkening, especially in areas like the face, gums, and scars. This is due to Imcivree’s action on melanocortin receptors involved in pigmentation.

• Injection site reactions
  Redness, swelling, itching, or discomfort at the injection site may occur. These are usually mild and resolve without intervention, but rotating injection sites helps minimize this issue.

• Nausea and vomiting
  Some patients, especially when starting treatment, may experience gastrointestinal discomfort. Taking the injection at a consistent time and on a full stomach may help reduce these effects.

• Headache and fatigue
  Occasional headaches or tiredness may be experienced, particularly in the early stages of treatment. These effects often diminish with continued use.

• Depression or mood changes
  Although rare, some patients have reported worsening depression or suicidal ideation. Mood should be closely monitored, especially in individuals with a history of mental health conditions.

• Abdominal pain or diarrhea
  Gastrointestinal symptoms such as stomach cramps or loose stools may occur but are generally self-limiting.

• Decreased sexual desire
  Alterations in libido have been noted in a small number of adult patients, although the clinical relevance remains under evaluation.

Yes, Imcivree is approved for pediatric use in children aged 6 years and older, provided they have a confirmed diagnosis of a genetic condition that causes MC4R pathway deficiency. Its safety and efficacy in this age group have been evaluated through clinical trials specifically designed for pediatric patients.

• Approved for age 6 and above
  The FDA has authorized Imcivree for children six years and older, making it a viable treatment for early-onset obesity caused by genetic mutations.

• Weight-based dosing
  Pediatric dosage is calculated based on body weight, ensuring appropriate and safe drug exposure across different age and size groups.

• Parental or caregiver administration
  In most cases, injections are administered by a parent or guardian until the child can self-administer with confidence.

• Clinical trial data in children
  Pediatric patients showed significant reductions in hunger and body weight in clinical studies, with effects observed as early as a few weeks into treatment.

• Monitoring for psychological well-being
  Because childhood obesity can affect mental health, regular psychological monitoring during treatment is essential, especially regarding mood changes or self-esteem.

• Adherence support is critical
  Establishing a routine around injections and follow-ups helps ensure adherence and optimize results in pediatric patients.

The time it takes for Imcivree to show noticeable effects can vary by individual. However, many patients begin to see a reduction in hunger within weeks and significant weight loss within a few months. The effectiveness of Imcivree depends on consistent use, proper dosing, and the individual’s genetic profile.

• Reduction in hunger can occur in 2–4 weeks
  Patients often notice less compulsive eating and better satiety soon after starting the medication.

• Weight loss typically begins within 1–2 months
  Initial weight reduction is modest but accelerates with consistent dosing over time.

• Peak effects usually seen by 3–6 months
  Many patients achieve substantial improvements in weight and hunger regulation during this period.

• Continued use enhances long-term benefits
  Sustained daily use is necessary to maintain appetite control and prevent relapse of hyperphagia.

• Effectiveness varies by genetic mutation
  Some mutations may respond more robustly to treatment, especially in cases with complete receptor deficiency.

• Lifestyle habits still contribute
  While not required for effectiveness, reinforcing healthy dietary patterns can complement treatment outcomes.

Yes, Imcivree is intended for chronic use, and its long-term safety profile is considered favorable in both adults and children. Clinical trials and real-world data suggest that Imcivree is well tolerated over extended periods when used appropriately and monitored regularly.

• Approved for continuous therapy
  Imcivree is not a short-term weight loss medication; it is designed for ongoing use to manage a chronic condition.

• No evidence of tolerance development
  Studies have not shown reduced effectiveness over time, indicating that long-term benefits can be sustained with consistent use.

• Regular monitoring recommended
  Patients should undergo routine assessments including weight, mood, metabolic markers, and injection site condition.

• Minimal long-term organ toxicity
  Unlike some weight-loss drugs, Imcivree has not been linked to liver or kidney toxicity with chronic use.

• Can be used across life stages
  The drug can be safely continued from childhood into adulthood, making it a viable lifelong therapy.

• Psychosocial improvements over time
  Sustained use often results in improved quality of life, including better social participation and emotional well-being.

If you miss a dose of Imcivree, it’s important to act based on how much time has passed since the missed injection. While missing one dose is generally not dangerous, maintaining consistency is essential for best results.

• Take the missed dose as soon as remembered
  If it’s only been a few hours, administer the injection as soon as possible to keep drug levels stable.

• Skip the dose if it’s almost time for the next
  If you are close to your next scheduled dose, skip the missed one and resume the regular dosing schedule. Do not double up.

• Avoid frequent missed doses
  Missing doses repeatedly can reduce treatment effectiveness and increase the return of symptoms like hunger and weight gain.

• Set reminders for dosing
  Using alarms or mobile apps can help ensure daily adherence, which is critical to maintaining appetite control.

• Store medication properly
  Make sure Imcivree is stored in the refrigerator to keep it ready and effective for each scheduled dose.

• Contact support if unsure
  If you’re uncertain about what to do after a missed dose, you can contact our support team or consult a healthcare provider for guidance.